GSK sale of Aspen stake a 'credit positive' move, says Moody's
Rating agency Moody's has described GlaxoSmithKline's decision to sell a 6.2% stake in Aspen Pharmacare as "credit positive". On 13 March, the pharmaceutical giant sold half of its 12.4% stake in South Africa-based Aspen Pharmacare Holdings for £574m, in what Moody's described as a "credit-positive
Read more